PREZISTA
Total Payments
$8.6M
Transactions
2,960
Doctors
590
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $15,661 | 8 | 0 |
| 2023 | $254,017 | 116 | 29 |
| 2022 | $467,895 | 183 | 5 |
| 2021 | $11.41 | 1 | 1 |
| 2020 | $4,326 | 3 | 1 |
| 2019 | $37,040 | 533 | 281 |
| 2018 | $3.0M | 1,139 | 277 |
| 2017 | $4.8M | 977 | 163 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.5M | 1,245 | 98.9% |
| Consulting Fee | $45,500 | 14 | 0.5% |
| Food and Beverage | $26,950 | 1,641 | 0.3% |
| Travel and Lodging | $23,633 | 58 | 0.3% |
| Education | $33.24 | 2 | 0.0% |
Payments by Type
Research
$8.5M
1,245 transactions
General
$96,116
1,715 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor Combined With Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically-suppressed, Human Immunodeficiency Virus Type 1 Infected Subjects | Janssen Research & Development, LLC | $3.0M | 5 |
| A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once-daily Single-tablet Regimen Versus Continuing the Current Regimen | Janssen Research & Development, LLC | $1.8M | 5 |
| A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once Daily Fixed Dose Combination Regimen Versus a Regimen Consisting of Darunavir/Cobicistat Fixed Dose Combination Coadministered With Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 Infected Subjects | Janssen Research & Development, LLC | $756,246 | 3 |
| A Phase 4 Randomized Active Controlled Open label Study to Evaluate the Safety and Tolerability of Switching to Once Daily Darunavir Cobicistat Emtricitabine Tenofovir Alafenamide DCFTAF Fixed dose Combination FDC Regimen in Virologically suppressed Human Immunodeficiency Virus Type 1 HIV1 Infected Participants Experiencing Rapid Weight Gain with an INI + TAFFTC ARV Regimen | Janssen Research & Development, LLC | $702,699 | 1 |
| A Phase 3, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed-dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-nave Human | Janssen Research & Development, LLC | $641,358 | 2 |
| A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once Daily Fixed Dose Combination Regimen Versus a Regimen Consisting of Darunavir/Cobicistat Fixed Do | Janssen Research & Development, LLC | $568,139 | 3 |
| A Single-dose, Open-label, Randomized, Crossover Study to Assess the Relative Bioavailability of the Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir | Janssen Research & Development, LLC | $475,571 | 0 |
| A Phase 3, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed-dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-nave Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects Receiving Care in a Test and Treat Model of Care | Janssen Research & Development, LLC | $310,411 | 2 |
| Mechanisms of Immune Reconstitution and Reduced Immune Activation Following Darunavir-based ART | Janssen Research & Development, LLC | $78,105 | 0 |
| A Single Arm, Open Label Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women | Janssen Research & Development, LLC | $37,491 | 0 |
| Clinical outcomes of oncedaily Darunavir in patients with Darunavir resistanceassociated mutations | Janssen Research & Development, LLC | $29,773 | 0 |
| Study to Evaluate Efficacy and Safety of Darunavir Cobicistat Emtricitabine Tenofovir Alafenamide DCFTAF Regimen Versus Boosted Protease Inhibitor bPI Along With Emtricitabine Tenofovir Disoproxil Fumarate FTCTDF Regimen in Virologically Suppressed HIV1 Infected Participants | Janssen Research & Development, LLC | $29,330 | 0 |
| Clinical outcomes of once daily Darunavir in patients with Darunavir resistance associated mutations | Janssen Research & Development, LLC | $4,312 | 0 |
| A Phase 3 Single arm Open label Study to Evaluate the Efficacy and Safety of Darunavir Cobicistat Emtricitabine Tenofovir Alafenamide DCFTAF Once Daily Fixed dose Combination FDC Regimen in Newly Diagnosed Antiretroviral Treatment nave Human Immunodeficiency Virus Type 1 HIV1 Infected Subjects Receiving Care in a Test and Treat Model of Care | Janssen Research & Development, LLC | $3,308 | 0 |
Top Doctors Receiving Payments for PREZISTA — Page 24
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Specialist | Dallas, TX | $4.47 | 1 |
| , M.D | Family Medicine | Miami, FL | $4.19 | 1 |
| , MD | Internal Medicine | Saint Louis, MO | $3.98 | 1 |
| , M.D | Family Medicine | Saint Louis, MO | $3.98 | 1 |
| , MD | Infectious Disease | Edison, NJ | $3.82 | 1 |
| , MD | Infectious Disease | Baltimore, MD | $3.75 | 1 |
| , MD | Infectious Disease | Jacksonville, FL | $3.41 | 1 |
| , MD | Internal Medicine | Baltimore, MD | $3.31 | 1 |
| , M.D | Infectious Disease | Riverdale, GA | $2.89 | 1 |
| , MD | Infectious Disease | Long Beach, CA | $2.68 | 1 |
| , M.D | Infectious Disease | Hartford, CT | $2.09 | 1 |
| , MD | Infectious Disease | Indianapolis, IN | $1.17 | 1 |
| Kathryn Robertson | — | Indianapolis, IN | $1.17 | 1 |
| , DO | Infectious Disease | Indianapolis, IN | $1.17 | 1 |
| , MD | Infectious Disease | West Palm Beach, FL | $0.99 | 1 |
| , MD | Infectious Disease | West Palm Beach, FL | $0.99 | 1 |
Ad
Manufacturing Companies
- Janssen Research & Development, LLC $8.5M
- Janssen Scientific Affairs, LLC $70,923
- Janssen Biotech, Inc. $18,211
- Janssen Pharmaceuticals, Inc $1,137
Product Information
- Type Drug
- Total Payments $8.6M
- Total Doctors 590
- Transactions 2,960
About PREZISTA
PREZISTA is a drug associated with $8.6M in payments to 590 healthcare providers, recorded across 2,960 transactions in the CMS Open Payments database. The primary manufacturer is Janssen Research & Development, LLC.
Payment data is available from 2017 to 2024. In 2024, $15,661 was paid across 8 transactions to 0 doctors.
The most common payment nature for PREZISTA is "Unspecified" ($8.5M, 98.9% of total).
PREZISTA is associated with 14 research studies, including "A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor Combined With Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically-suppressed, Human Immunodeficiency Virus Type 1 Infected Subjects" ($3.0M).